Melody Smith

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

22h-index3.1kcitations129works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(71), Hematopoietic Stem Cell Transplantation(18), Biosimilars and Bioanalytical Methods(17), Immune Cell Function and Interaction(16), Biomedical Ethics and Regulation(15)

Publications129 total

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT
Blood·2025Open Access
Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)
Blood·2025Open Access
Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy
Blood·2025Open Access
From response to rupture: Evaluating GI perforation after CD19 CAR‑T in LBCL
Blood·2025Open Access
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias
2025Open Access
Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignancies
Current Opinion in Immunology·2025Open Access
Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults
Open Forum Infectious Diseases·2025· 1 citedOpen Access
NMR RDC refinement of the catalytic domain of the SARS-CoV-2 monomeric Main Protease (MPROH41Q,10-306)
2025
NMR RDC refinement of the helical domain of the SARS-CoV-2 monomeric Main Protease (MPROH41Q,10-306)
2025
Kitlo hematopoietic stem cells exhibit distinct lymphoid-primed chromatin landscapes that enhance thymic reconstitution
Nature Communications·2025· 2 citedOpen Access
Hematopoietic cell transplantation and cellular therapy 4: adoptive cellular therapy
2025
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Blood Advances·2025· 1 citedOpen Access
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy
Blood Advances·2025· 2 citedOpen Access
Figure S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
2025Open Access
Figure S10 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
2025Open Access
Table S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
2025Open Access
Table S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
2025Open Access
Figure S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
2025Open Access
Data from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
2025Open Access
Figure S11 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
2025Open Access
page 1 of 7Next →

Frequent Co-authors

Saurabh Dahiya(14), Matthew J. Frank(14), David B. Miklos(14), Marcel R.M. van den Brink(12), Wen‐Kai Weng(12), Miguel‐Angel Perales(11), Lori Muffly(11), Sergio Giralt(10), Parveen Shiraz(10), Bita Sahaf(10), Robert S. Negrin(10), Surbhi Sidana(10), Jonathan U. Peled(9), Sally Arai(9), Andrew R. Rezvani(9), Judith A. Shizuru(9), Ying Taur(8), Laura Johnston(8), Everett Meyer(8), Sushma Bharadwaj(8)